← Back

NVONovo Nordisk

$45.30-2.80%Real quote · delayedPharmaPharma & biotech · 15 peers →

🏛️ Company factsSEC filings + FINRA official data

short activity within its normal range.

Short volume

43.8%

20d avg 42.3% · normal

No SEC filings for this ticker (non-US filer or newly listed)

Expectation reliability Medium · 61/100

Nasdaq analyst consensus · the pre-news baseline

Next quarter (Sep 2026) consensus$0.80Estimate range $0.74 ~ $0.86 · 5 analystsRevisions (4w):↑2

History: actual vs consensusavg +20%

The takeaway

This company habitually beats by +20% — the next report has to clear that bar to count as good news.

Analyst estimates, not our forecast · not investment advice

0 direct · 1 2nd-order · 0 thematic

Ranked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)

#1▼0.18%2nd-order3 Things That Matter Most for Eli Lilly Now10d ago
By highlighting Lilly's competitive edge in GLP-1 drugs, the article indirectly underscores market-share pressure on rival Novo Nordisk.
Impact chain →
Also named: LLY · UNH

Drag to pan, scroll to zoom · real daily bars and volume

The 25 engine calls on this chart (hit / miss / pending) are Pro — price and volume only for now▂ volume

📜 Call history (newest first

🔒 Pro only

25 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view

🔒 Pro only

Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.